REGENXBIO Inc. (RGNX), a clinical-stage biotechnology company pioneering AAV gene therapies, is preparing to share new interim data from its Duchenne muscular dystrophy program.
The company's lead neuromuscular asset, RGX-202, is a next-generation, one-time gene therapy designed to deliver a novel microdystrophin gene using its NAV AAV8 vector.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.